LEVEL Phase 3 Misses Primary Endpoint
Tenax Therapeutics reported that the 241-patient Phase 3 LEVEL study of oral levosimendan, TNX-103, did not improve six-minute walk distance or the key Kansas City Cardiomyopathy Questionnaire symptom endpoint in pulmonary hypertension associated with…
